Skip to main content

Table 4 Statistical evaluation of the benefit of diverse chemotherapy regimens used for adjuvant treatment in patients with T4 UICC II

From: Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer

Group comparisons

 

FUFOL

FUFOL + Oxaliplatin

Others + Oxaliplatin

Other substances

Substance unknown

No chemotherapy

 

Chemotheraphy

Chi-

 

Chi-

 

Chi-

 

Chi-

 

Chi-

 

Chi-

 
 

group

square

Sig.

square

Sig.

square

Sig.

square

Sig.

square

Sig.

square

Sig.

Long Rank

FUFOL

  

,072

,788

.

.

,013

,909

,563

,453

4,179

,041

(Mantel-Cox)

FUFOL + Oxaliplatin

,072

,788

  

,074

,785

,192

,661

,015

,901

3,934

,047

 

Others + Oxaliplatin

.

.

,074

,785

  

,118

,732

.

.

,628

,428

 

Other substances

,013

,909

,192

,661

,118

,732

  

,223

,636

4,370

,037

 

Substance unknown

,563

,453

,015

,901

  

,223

,636

  

,681

,409

 

No chemotheraphy

4,179

,041

3,934

,047

,628

,428

4,370

,037

,681

,409